Brief: Xspray Pharma Submits XS003 To FDA; Review Expected Within 60 Days
19/08/2025 17:31
Aug 19 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST: XSPRAY PHARMA SUBMITS XS003 TO THE FDA – THE COMPANY’S SECOND PRODUCT CANDIDATE FROM THE HYNAP PLATFORM XSPRAY PHARMA AB (PUBL) - FDA REVIEW OF XS003 EXPECTED WITHIN 60 DAYS Source text: ID:nBw4tnrca Further company coverage: XSPRAY.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003